COMMD5 is poorly expressed in gastric cancer. Rosiglitazone, a synthetic PPARγ agonist, is associated with COMMD5 up-regulation in the inhibition of gastric carcinogenesis (85). Here, COMMD5 is linked to gastric cancer.